Subcutaneous Immunoglobulin (SCIG) Market Analysis: In-Depth Look at Industry Trends, Growth Drivers, and Future Potential to 2033

"The new report published by The Business Research Company, titled ""Subcutaneous Immunoglobulin (SCIG) Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the subcutaneous immunoglobulin market size has grown rapidly in recent years. It will grow from $11.19 billion in 2023 to $12.72 billion in 2024 at a compound annual growth rate (CAGR) of 13.7%. The subcutaneous immunoglobulin market size is expected to see rapid growth in the next few years. It will grow to $21.38 billion in 2028 at a compound annual growth rate (CAGR) of 13.9%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

Impact Of Secondary Immunodeficiency Diseases On The Subcutaneous Immunoglobulin Market
The increase in the prevalence of secondary immunodeficiency diseases is expected to propel the growth of the subcutaneous immunoglobulin market going forward. Secondary immunodeficiency diseases are conditions with a reduced or compromised immune system caused by sources other than the immune system itself. The prevalence of secondary immunodeficiency diseases is driven by various factors such as aging populations, the use of immunosuppressive treatments, and environmental toxins. Subcutaneous immunoglobulin therapy provides antibodies to help strengthen the weakened immune system, especially in chronic disorders such as HIV or autoimmune diseases, thereby preventing infections and supporting immunological function during treatment. For instance, in October 2023, according to the UK Health Security Agency, a UK-based government agency, reported 3,805 new HIV diagnoses in England in 2022, representing a 22% rise from the previous year. Therefore, the increase in the prevalence of secondary immunodeficiency diseases is driving the growth of the subcutaneous immunoglobulin market.

Rising Neurological Disorders Fuel Growth In The Subcutaneous Immunoglobulin Market

The increasing number of neurological disorders is expected to propel the growth of the subcutaneous immunoglobulin market going forward. A neurological disorder is any disorder of the nervous system that includes anatomical, biochemical, or electrical abnormalities in the brain, spinal cord, or peripheral nerves such as acute spinal cord injury, alzheimer's dementia, amyotrophic lateral sclerosis (ALS), ataxia, brain tumors, and others. Neurological disorders are increasing due to various factors such as aging populations, environmental toxins, genetic predispositions, and lifestyle changes. Subcutaneous immunoglobulin therapy can be beneficial in neurological disorders by providing antibodies that modulate the immune response, reduce inflammation, and stabilize neuromuscular junctions, potentially slowing disease progression and improving symptoms. For instance, in March 2022, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization reported that 6.5 million Americans aged 65 and older are currently living with Alzheimer's dementia, with projections indicating this number could reach 13.8 million by 2060. Therefore, the increasing number of neurological disorders is driving the growth of the subcutaneous immunoglobulin market.

Advancements In Subcutaneous Immunoglobulin Therapy For Primary Immunodeficiency Diseases
Major companies operating in the subcutaneous immunoglobulin market are developing subcutaneous human-klhw, a unique formulation containing human immune globulins (Ig) that strengthens the immune system. Subcutaneous human-klhw is used for subcutaneous administration, developed for treating primary immunodeficiency diseases in human body. For instance, in March 2022, Grifols S.A., a Spain-based pharmaceutical company, launched XEMBIFY 20% subcutaneous immunoglobulin (SCIG). It is specifically designed to treat primary immunodeficiency, meeting a significant medical need for people with weakened immune systems. XEMBIFY is a ready-to-use formulation that simplifies the treatment process and increases patient convenience. It is stable at room temperature for up to 24 months, avoiding the need for refrigeration during storage and transportation, which can be extremely useful in a variety of healthcare settings.

The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented -

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=15935&type=discount

Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy's Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc. , Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

Contents of the report:
1. Executive Summary
2. Subcutaneous Immunoglobulin (SCIG) Market Report Structure
3. Subcutaneous Immunoglobulin (SCIG) Market Trends And Strategies
4. Subcutaneous Immunoglobulin (SCIG) Market - Macro Economic Scenario
5. Subcutaneous Immunoglobulin (SCIG) Market Size And Growth
…..
27. Subcutaneous Immunoglobulin (SCIG) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.